Emerging targeted drug delivery strategies toward ovarian cancer.

Abstract

Ovarian cancer is a high-mortality malignancy in women. The contemporary clinical chemotherapy with classic cytotoxic drugs, targeted molecular inhibitors would mostly fail when ovarian cancer cells become drug-resistant or metastasize through the body or when patients bare no more toleration because of strong adverse effects. The past decade has spotted varying targeted delivery systems including antibody-drug conjugates (ADCs), peptide/folate/aptamer-drug conjugates, polymer-drug conjugates, ligand-functionalized nanomedicines, and dual-targeted nanomedicines that upgrade ovarian cancer chemo- and molecular therapy effectively in preclinical/clinical settings via endowing therapeutic agents selectivity and bypassing drug resistance as well as lessening systemic toxicity. The targeted delivery approaches further provide means to potentiate emergent treatment modalities such as molecular therapy, gene therapy, protein therapy, photodynamic therapy, dual-targeting therapy and combination therapy for ovarian cancer. This review highlights up-to-date development of targeted drug delivery strategies toward advanced, metastatic, relapsed, and drug resistant ovarian cancers.

• Authors: Zhe Wang, Fenghua Meng, Zhiyuan Zhong
• Journal: Advanced drug delivery reviews (Adv Drug Deliv Rev) Vol. 178 Pg. 113969 (11 2021) ISSN: 1872-8294 [Electronic] Netherlands
• PMID: 34509574 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2021 Elsevier B.V. All rights reserved.

Chemical References

• Antineoplastic Agents

Topics

• Antineoplastic Agents (chemistry, therapeutic use)
• Drug Delivery Systems
• Female
• Humans
• Nanomedicine
• Nanoparticles (chemistry)
• Ovarian Neoplasms (drug therapy)
• Photochemotherapy